New pivotal data demonstrate clinical benefit of Roche ’s glofitamab, a potential first-in-class bispecific antibody for people with aggressive lymphoma
Data to be presented for the first time at ASCO and EHA 2022 showglofitamab induces high and durable complete response rates in people with heavily pre-treated diffuse large B-cell lymphoma1Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphomaGlofitamab is part of Roche ’s industry-leading CD20xCD3 bispecific antibody developmentprogramme, which aims to address the diverse needs and preferences of people with blood cancersBasel, 27 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new pivotal data on i...
Source: Roche Media News - May 27, 2022 Category: Pharmaceuticals Source Type: news
New pivotal data demonstrate clinical benefit of Roche ’s glofitamab, a potential first-in-class bispecific antibody for people with aggressive lymphoma
Data to be presented for the first time at ASCO and EHA 2022 showglofitamab induces high and durable complete response rates in people with heavily pre-treated diffuse large B-cell lymphoma1Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphomaGlofitamab is part of Roche ’s industry-leading CD20xCD3 bispecific antibody developmentprogramme, which aims to address the diverse needs and preferences of people with blood cancersBasel, 27 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new pivotal data on i...
Source: Roche Investor Update - May 27, 2022 Category: Pharmaceuticals Source Type: news
Roche ’s Polivy combination approved by European Commission for people with previously untreated diffuse large B-cell lymphoma
First new treatment option in more than 20 years to show a clinically meaningful improvement in progression-free survival is approved for people with previously untreated diffuse large B-cell lymphoma (DLBCL)Approval is based on pivotal data from the phase III POLARIX study, where Polivy plus R-CHP significantly improved progression-free survival with comparable safety versus the standard of care, R-CHOPFirst-line treatment with Polivy plus R-CHP has the potential to reduce the burden on patients and healthcare systems, associated with disease progression ¹Basel, 25 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today anno...
Source: Roche Investor Update - May 25, 2022 Category: Pharmaceuticals Source Type: news
Roche ’s Polivy combination approved by European Commission for people with previously untreated diffuse large B-cell lymphoma
First new treatment option in more than 20 years to show a clinically meaningful improvement in progression-free survival is approved for people with previously untreated diffuse large B-cell lymphoma (DLBCL)Approval is based on pivotal data from the phase III POLARIX study, where Polivy plus R-CHP significantly improved progression-free survival with comparable safety versus the standard of care, R-CHOPFirst-line treatment with Polivy plus R-CHP has the potential to reduce the burden on patients and healthcare systems, associated with disease progression ¹Basel, 25 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today anno...
Source: Roche Media News - May 25, 2022 Category: Pharmaceuticals Source Type: news
Roche ’s Polivy combination approved by European Commission for people with previously untreated diffuse large B-cell lymphoma
First new treatment option in more than 20 years to show a clinically meaningful improvement in progression-free survival is approved for people with previously untreated diffuse large B-cell lymphoma (DLBCL)Approval is based on pivotal data from the phase III POLARIX study, wherePolivy plus R-CHP significantly improved progression-free survival with comparable safety versus the standard of care, R-CHOPFirst-line treatment withPolivy plus R-CHP has the potential to reduce the burden on patients and healthcare systems, associated with disease progression1Basel, 25 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announce...
Source: Roche Investor Update - May 25, 2022 Category: Pharmaceuticals Source Type: news
Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leadinghaematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncol...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news
Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data on glofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading haematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Onc...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news
Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading haematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Onco...
Source: Roche Investor Update - May 24, 2022 Category: Pharmaceuticals Source Type: news
Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leadinghaematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncol...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news
Trial May Set Standard for Steroid Therapy in Duchenne Muscular Dystrophy
(MedPage Today) -- SEATTLE -- Prednisone or deflazacort given every day were superior to prednisone on a 1o-days-on, 10-days-off schedule for boys with Duchenne muscular dystrophy (DMD), a researcher reported.
In the international randomized... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - April 27, 2022 Category: Endocrinology Source Type: news
CHMP recommends EU conditional approval of Roche ’s potential first-in-class bispecific antibody mosunetuzumab for people with relapsed or refractory follicular lymphoma
If approved, mosunetuzumab would be the first CD20xCD3 T-cell engaging bispecific antibody available to treat follicular lymphoma (FL) offering a new, off-the-shelf, fixed-duration treatment optionThe recommendation is based on the GO29781 study where mosunetuzumab induced high complete response rates, with the majority of complete responses lasting for at least 18 months in people with heavily pretreated FLBasel, 22 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval under conditional marketin...
Source: Roche Investor Update - April 22, 2022 Category: Pharmaceuticals Source Type: news
CHMP recommends EU conditional approval of Roche ’s potential first-in-class bispecific antibody mosunetuzumab for people with relapsed or refractory follicular lymphoma
If approved, mosunetuzumab would be the first CD20xCD3 T-cell engaging bispecific antibody available to treat follicular lymphoma (FL) offering a new, off-the-shelf, fixed-duration treatment optionThe recommendation is based on the GO29781 study where mosunetuzumab induced high complete response rates, with the majority of complete responses lasting for at least 18 months in people with heavily pretreated FLBasel, 22 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval under conditional marketin...
Source: Roche Media News - April 22, 2022 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Reports Q1 2022 Results
New Brunswick, N.J. (April 19, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2022. “Our first quarter results demonstrate strong performance across the enterprise, despite macro-economic headwinds. I am incredibly proud of Johnson & Johnson’s 144,000 employees for their relentless passion and Credo-based commitment to delivering transformative healthcare solutions to patients and customers around the world,” said Joaquin Duato, Chief Executive Officer. “Looking ahead, I remain confident in the future of Johnson & Johnson as we continue advancing our portfolio and inno...
Source: Johnson and Johnson - April 19, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
Optimal Treatment Regimen for Muscular Dystrophy Identified? Optimal Treatment Regimen for Muscular Dystrophy Identified?
Children treated with either daily prednisone or daily deflazacort (Emflaza) have better motor function than those receiving a standard prednisone regimen.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 6, 2022 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
CHMP recommends EU approval of Roche ’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma
Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people with previously untreated diffuse large B-cell lymphoma (DLBCL) over the standard of care in more than 20 yearsApproximately 40% of people with previously untreated DLBCL are not cured with the current standard of care and face a poor prognosis [1,2]Recommendation is based on pivotal data from the phase III POLARIX studyBasel, 25 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Pol...
Source: Roche Investor Update - March 25, 2022 Category: Pharmaceuticals Source Type: news
